Jubilant Pharmova sells API business to Biosys subsidiary

** Jubilant Pharmova Limited [BSE:JUBLPHARMA] has announced the sale and transfer of its Active Pharmaceutical Ingredients (API) business to Jubilant Biosys Limited (JBL), a wholly-owned subsidiary, effective September 1, 2025, subject to customary approvals. The transaction involves a slump sale basis transfer, with the purchase consideration to be determined based on the book value of assets and liabilities of the API business as of the appointed date, under Rule 11UAE prescribed by the Income Tax Rules' 1962. The consideration will primarily be discharged through the issuance of shares. The API business achieved a turnover of INR 609 crores, representing 8.35% of Jubilant Pharmova's consolidated turnover for the financial year ended March 31, 2025. Its net worth is valued at INR 666.5 crores, accounting for 10.68% of the company’s consolidated net worth as of March 31, 2025. Jubilant Pharmova aims to achieve 2x revenue growth from the FY24 levels, improve EBITDA margins to more than 15%. As Jubilant Biosys Limited is a wholly owned subsidiary and whose accounts will be consolidated, the transaction is at arm's length.